Zimmer Biomet Holdings, Inc. · NYSE (us_market)
Healthcare · Medical Devices · United States
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-10-22$103.98 RISE2026-01-28$85.71 PEAK2026-02-26$100.99 127d | -17.6% 98d | Missed | Missed | — | — | +17.8% 29d | Missed |
DROP2025-03-31$113.18 RISE2025-08-01$90.62 PEAK2025-08-22$107.71 144d | -19.9% 123d | Missed | Missed | — | — | +18.9% 21d | Missed |
DROP2025-03-31$113.18 RISE2025-06-17$90.21 PEAK2025-08-22$107.71 144d | -20.3% 78d | Missed | Missed | — | — | +19.4% 66d | Missed |
DROP2023-06-30$145.60 RISE2023-10-12$102.72 PEAK2024-01-08$121.97 192d | -29.5% 104d | Missed | Missed | — | — | +18.7% 88d | Missed |
DROP2022-04-20$133.85 RISE2022-07-14$101.65 PEAK2022-09-12$119.27 145d | -24.1% 85d | Missed | Missed | — | — | +17.3% 60d | Missed |
DROP2021-10-25$146.63 RISE2022-02-07$108.42 PEAK2022-04-20$133.85 177d | -26.1% 105d | Missed | Missed | — | — | +23.5% 72d | Missed |
DROP2020-02-19$155.36 RISE2020-06-25$111.94 PEAK2020-09-16$141.68 210d | -27.9% 127d | Missed | Missed | — | — | +26.6% 83d | Missed |
DROP2020-02-14$155.73 RISE2020-03-18$78.28 PEAK2020-06-05$133.40 112d | -49.7% 33d | Missed | Missed | — | — | +70.4% 79d | Missed |
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destocking have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 1.2% has lagged the S&P 500’s 9.8% climb.
Over the past six months, Zimmer Biomet’s shares (currently trading at $85.45) have posted a disappointing 12.4% loss, well below the S&P 500’s 9.1% gain. This might have investors contemplating their next move.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the best robotic surgery stocks to buy. Canaccord cut the price target on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to $83 from $93 on April 29, and maintained a Buy rating on the shares. The firm stated that the company delivered a solid fiscal Q1 to start the year, […]
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the best robotic surgery stocks to buy. Canaccord cut the price target on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to $83 from $93 on April 29, and maintained a Buy rating on the shares. The firm stated that the company delivered a solid fiscal Q1 to start the year, […]
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is payable on or about July 31, 2026 to stockholders of record as of the close of business on June 25, 2026.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Orthopedic Soft Tissue Repair Market size & share revenue was valued at approximately USD 7.26 Billion in 2025 and is expected to reach USD 7.96 Billion in 2026 and is expected to reach around USD 15.38 Billion by 2035, at a CAGR of 9.6 between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Arthrex Inc., Stryke
Shares of medical device company Zimmer Biomet (NYSE:ZBH) jumped 4.9% in the afternoon session after the company announced it increased its share repurchase expectations for fiscal year 2026.
Shares of medical device company Zimmer Biomet (NYSE:ZBH) jumped 4.9% in the afternoon session after the company announced it increased its share repurchase expectations for fiscal year 2026.
As Zimmer Biomet has lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.
Zimmer Biomet Holdings (ZBH) has drawn fresh attention after announcing plans to repurchase up to US$1b of its common stock in fiscal 2026, representing a US$250m increase under its existing authorization. See our latest analysis for Zimmer Biomet Holdings. Despite the enlarged 2026 repurchase plans and upcoming appearance at the Bank of America Global Healthcare Conference, the stock’s recent momentum has been weak, with the 30 day share price return down 14.37% and the 1 year total...
Zimmer Biomet Holdings (ZBH) has drawn fresh attention after announcing plans to repurchase up to US$1b of its common stock in fiscal 2026, representing a US$250m increase under its existing authorization. See our latest analysis for Zimmer Biomet Holdings. Despite the enlarged 2026 repurchase plans and upcoming appearance at the Bank of America Global Healthcare Conference, the stock’s recent momentum has been weak, with the 30 day share price return down 14.37% and the 1 year total...
ISRG's da Vinci 5 is driving stronger utilization and procedure growth, but can higher throughput and after-hours surgeries sustain momentum?
ISRG's da Vinci 5 is driving stronger utilization and procedure growth, but can higher throughput and after-hours surgeries sustain momentum?
Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said: For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I […]
Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said: For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I […]
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ZBH | -0.69% | -17.25% | -8.44% | -10.68% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.66% | -11.53% | -5.00% | -23.36% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 8.83M | $800.06M | 0.03% | Unchanged | 2026-03-31 |
| FidelityFMR | fundamental | 100.8K | $9.11M | 0.00% | Trimmed-12.8% | 2026-03-31 |
| RenTech | quant | 60.5K | $5.47M | 0.01% | New | 2026-03-31 |
| Wellington | fundamental | 44.4K | $4.01M | 0.00% | Added+1.6% | 2026-03-31 |
| Bridgewater | macro | 34.0K | $3.07M | 0.01% | Added+8.9% | 2026-03-31 |
| TwoSigma | quant | 32.0K | $2.89M | 0.00% | Added+898.4% | 2026-03-31 |
| DEShaw | quant | 9.1K | $826.98K | 0.00% | Trimmed-71.5% | 2026-03-31 |
| TRowePrice | fundamental | 8.00M | $723.34K | 0.08% | Trimmed-41.3% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-27 | HAGEMANN ROBERT | Director | A Grant / award(deriv) | 1,517 | — | +$0 |
| 2026-05-27 | HAGEMANN ROBERT | Director | A Grant / award(deriv) | 875 | — | +$0 |
| 2026-05-27 | HIGGINS ARTHUR J | Director | A Grant / award(deriv) | 1,517 | — | +$0 |
| 2026-05-27 | HIGGINS ARTHUR J | Director | A Grant / award(deriv) | 875 | — | +$0 |
| 2026-05-27 | Jafry Syed A. | Director | A Grant / award(deriv) | 1,517 | — | +$0 |
| 2026-05-27 | Jafry Syed A. | Director | A Grant / award(deriv) | 875 | — | +$0 |
| 2026-05-27 | Kolli Sreelakshmi | Director | A Grant / award(deriv) | 1,517 | — | +$0 |
| 2026-05-27 | Kolli Sreelakshmi | Director | A Grant / award(deriv) | 875 | — | +$0 |
| 2026-05-27 | Kurdikar Devdatt | Director | A Grant / award(deriv) | 1,517 | — | +$0 |
| 2026-05-27 | Kurdikar Devdatt | Director | A Grant / award(deriv) | 875 | — | +$0 |
| 2026-05-27 | Shapiro Louis | Director | A Grant / award(deriv) | 1,517 | — | +$0 |
| 2026-05-27 | Shapiro Louis | Director | A Grant / award(deriv) | 875 | — | +$0 |
| 2026-05-27 | Hilado Maria Teresa | Director | A Grant / award(deriv) | 1,517 | — | +$0 |
| 2026-05-27 | Hilado Maria Teresa | Director | A Grant / award(deriv) | 875 | — | +$0 |
| 2026-05-27 | BERNARD BETSY J | Director | A Grant / award(deriv) | 1,517 | — | +$0 |
| 2026-05-27 | BERNARD BETSY J | Director | A Grant / award(deriv) | 875 | — | +$0 |
| 2026-05-27 | Farrell Michael J. | Director | A Grant / award(deriv) | 1,517 | — | +$0 |
| 2026-05-27 | Farrell Michael J. | Director | A Grant / award(deriv) | 875 | — | +$0 |
| 2026-05-05 | Stellato Paul A | VP, Controller, CAO | A Grant / award(deriv) | 9,232 | — | +$0 |
| 2026-04-03 | Noor Jehanzeb | See remarks below. | M Option exercise(deriv) | 6,626 | — | +$0 |
| 2026-04-03 | Noor Jehanzeb | See remarks below. | F Tax withholding | 1,677 | $90.67 | −$152.1K |
| 2026-04-03 | Noor Jehanzeb | See remarks below. | M Option exercise | 6,626 | — | +$0 |
| 2026-04-02 | Farrell Michael J. | Director | A Grant / award(deriv) | 421 | — | +$0 |
| 2026-04-02 | HAGEMANN ROBERT | Director | A Grant / award(deriv) | 309 | — | +$0 |
| 2026-04-02 | Kurdikar Devdatt | Director | A Grant / award(deriv) | 154 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 2.01 | — | — |
| 2026-04-28 | 1.86 | 2.09 | +12.21% |
| 2026-02-10 | 2.40 | 2.42 | +0.93% |
| 2025-11-05 | 1.87 | 1.90 | +1.83% |
| 2025-08-07 | 1.18 | 0.77 | -34.67% |
| 2025-05-05 | 1.77 | 1.81 | +2.27% |
| 2025-02-06 | 2.29 | 2.31 | +0.76% |
| 2024-10-30 | 1.74 | 1.74 | +0.20% |
| 2024-08-07 | 1.99 | 2.01 | +0.93% |
| 2024-05-02 | 1.87 | 1.94 | +3.75% |
| 2024-02-08 | 2.16 | 2.20 | +2.01% |
| 2023-11-07 | 1.60 | 1.65 | +2.86% |
| 2023-08-01 | 1.81 | 1.82 | +0.41% |
| 2023-05-02 | 1.64 | 1.89 | +15.20% |
| 2023-02-03 | 1.83 | 1.88 | +2.76% |
| 2022-11-02 | 1.56 | 1.58 | +1.58% |